Orphan Technologies starts OT-58 trial for homocystinuria treatment breakthrough

Swiss pharmaceutical company Orphan Technologies has begun dosing patients in a Phase 1/2 trial (CBS-HCY-01) to assess the safety and efficacy of its modified recombinant ... Read More